



Biocon Limited

20th KM Hosur Road
Electronics City
Bangalore 560 100, India
T 91 80 2808 2808
F 91 80 2852 3423
CIN : L24234KA1978PLC003417

Date of submission: November 12, 2018

www.biocon.com

To The Secretary BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code - 532523	To The Secretary National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050 Scrip Code- BIOCON
---	---

Dear Sir/Madam,

Sub: Biocon's Generic Formulations Facility in Bengaluru completes U.S. FDA Inspection with No 483 observations

Ref: Regulations 30 of SEBI Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015.

Pursuant to Regulation 30 of the SEBI LODR Regulations, 2015, please find below the "Company Statement" on the subject matter.

*"This is to inform you that the U.S. FDA conducted a pre approval inspection of our new Oral Solid Dosage Forms manufacturing facility at Biocon Park, Bengaluru, from Nov 05– Nov 09, 2018. **The audit concluded without any observations and no Form 483 was issued.** The successful audit of this site reflects our strong commitment to quality and cGMP compliance." -Company Spokesperson.*

We request you to kindly take this to your records as per the requirement of LODR and oblige.

Thanking You,
Yours faithfully
For Biocon Limited

Satish Kumar S S
Company Secretary